Member Info for Laura2022

Physiomics plc

Great to share the exciting news from Beyond Blood Diagnostics, who we’re delighted to be partnering with for our Innovate UK PREDICT-Onc project, which started in November last year! We are looking forward to the results of this transformative project for cancer diagnostics and patient care. Congrats to the team! 🎉

Beyond Blood Diagnostics

Today the National Research Council of Canada has announced their investment for Canada-UK quantum collaborations. We are proud to have been selected as the only company to receive funding for the development of new quantum technologies in the diagnostic sector from this initiative. This is testament to how cutting technology is enabled by cross-border collaborations between innovative startups, SMEs and academia

Fantastic spot Ralph

Would be good

Seems to me these resources companies that will never see revenues are the worse ,CEOs who are inept amd corrupt

Revenue generating stocks at least have a chance

Thanks Trench

Bbc article 1hr ago

This is weakest recession by a long way

Article in BBC

I am in agreement that the pipeline needs converted.and they i am sure will having publicly stated it

Also , as you alluded to before Christmas, Peter has great track record so I see him as a dynamic kind of person

I will listen again to the US section of the presentation

It didn't state it was years down the line from what I remember , but I will listen again

I assume with the more circumspect postings you nonlinear have an investment

Apologies if I've read this incorrectly KingH

250,000 at 1.4p

KingH

This was what they said re:pipeline

I agree with you that we like to see alot more converted HOWEVER in the Jan 2024 he clearly states pipeline momentum.

Have you managed to relay ýour thoughts to Peter ?

17th November. (50 minutes) , had an initial listen and a good  slide fron Peter which broke down the 36 project into various sections and that pipeline was £1mln and can be a "top up process" into this pot. The current cash of over £700,000 is good for the foreseeable future and not less than 12-15mths  He said there are 9 of these which are ready to be signed

Starting

The new CEO gave clear reasons in the presentation why he is excited about taking the helm and said he would deliver on the pipeline and make PYC profitable

Jim previously explained that contracts are generally between £60k and £200k amd with 20-30 pipeline it will be a mixture

Looking forward to more contracts

I believe its because client confidentiality is not applicable as the client is already public?

As tesco says ,every kittle helps

This Sheffield addition alluded to by Jim in the Nov presentation

2 contracts wins in 10 days now,let's see this continue

chosen by The University of Sheffield (the "University") to support a grant funded project focused on an insect (Fruit fly) model of cancer treatment.  The value of this work to Physiomics will be £45k and will commence in the second half of this calendar year.  The work is in support of one of seven cancer-focused projects recently announced by the University (https://www.sheffield.ac.uk/news/future-cancer-research-yorkshire-receives-ps89-million-funding-boost), all of which will be funded by Yorkshire Cancer Research.

You wonder why companies take these CLN type funding options as they always drag on the shares ...

The science and assets here are really good

It is clear he wants to engage with shareholders so it would be an option for shareholders to email him with specific queries now debull has kindly posted the contact email

Dr Peter Sargent, CEO, commented:

“I am thrilled to take on the role of CEO and director of Physiomics. Having had time to get to know the business and meet many of our clients and partners over these last few months, I can see many exciting opportunities ahead for us. I look forward to speaking to shareholders next week and over the course of 2024.”

 

Further information on Dr Sargent:

Prior to joining Physiomics in September 2023, Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his other previous roles, Dr Sargent has also been Head of Business Development for the UK’s National Institute for Health and Care Research (NIHR), leading a team supporting global life science businesses access to funding and research infrastructure in the UK

Have you tried emailing Debull ?

I can't believe he would put his neck on line in first UK CEOjob in the interview and say what he did about pipeline/building company....if he wasn't absolutely sure that FY would be the record revenues outlined in late 2023

The March update will be the audited 6mths results from July to Dec 2023 + any other forward looking

I agree with Truro ...just look at some of the awful non revenue companies and lifestyle directors elsewhere

Having said that ,they have 10-30 prospects to convert and it would Nice for Oeter to exercise his 1ßt options immediately

Placing news just released